Captor Therapeutics Spolka Akcyjna Third Quarter 2023 Earnings: zł3.65 loss per share (vs zł2.04 loss in 3Q 2022)
Captor Therapeutics Spolka Akcyjna (WSE:CTX) Third Quarter 2023 Results
Key Financial Results
- Revenue: zł2.81m (up 154% from 3Q 2022).
- Net loss: zł15.8m (loss widened by 85% from 3Q 2022).
- zł3.65 loss per share (further deteriorated from zł2.04 loss in 3Q 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Captor Therapeutics Spolka Akcyjna Earnings Insights
Looking ahead, revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe.
Performance of the market in Poland.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
We don't want to rain on the parade too much, but we did also find 3 warning signs for Captor Therapeutics Spolka Akcyjna that you need to be mindful of.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About WSE:CTX
Captor Therapeutics Spolka Akcyjna
A biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases.
Excellent balance sheet slight.